Brief: Neurobo Pharmaceuticals' Da-1241 In Combination With Semaglutide Improves Liver Fibrosis And Demonstrates Additive Hepatoprotective Effects In Pre-Clinical Mash Models Compared To Either Treatment, Alone

MetaVia

22/05/2024 13:38

May 22 (Reuters) - Neurobo Pharmaceuticals Inc  NRBO.O :
    * NEUROBO PHARMACEUTICALS' DA-1241 IN COMBINATION WITH
SEMAGLUTIDE
IMPROVES LIVER FIBROSIS AND DEMONSTRATES ADDITIVE
HEPATOPROTECTIVE EFFECTS IN PRE-CLINICAL MASH MODELS COMPARED TO
EITHER TREATMENT, ALONE
    * NEUROBO PHARMACEUTICALS SEES REPORTING TOP-LINE DATA FROM
BOTH
PARTS OF ONGOING PHASE 2A CLINICAL TRIAL IN MASH IN Q4 OF THIS
YEAR

Source text for Eikon:  ID:nPn5Mdlqza 
Further company coverage:  NRBO.O 

 ((Reuters.Briefs@thomsonreuters.com;))